Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Pancreatic Neoplasms 5Neoplasms 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Triple Negative Breast Neoplasms 4Melanoma 4Leukemia, Myelomonocytic, Chronic 4Carcinoma, Renal Cell 4Breast Diseases 4Urinary Bladder Neoplasms 3Thoracic Neoplasms 3Respiratory Tract Neoplasms 3Lymphoma 3Lung Diseases 3Leukemia, Myelomonocytic, Acute 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Congenital Abnormalities 3Colonic Neoplasms 3Bronchial Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Uveal Melanoma 2Uterine Cervical Neoplasms 2Sezary Syndrome 2Recurrence 2Rectal Neoplasms 2

Interventions

Cyclophosphamide 32Etoposide 18romidepsin 17fludarabine 17Vincristine 17Doxorubicin 16Rituximab 14Prednisone 14Melphalan 14Gemcitabine 13Brentuximab Vedotin 13Lenalidomide 12Peripheral Blood Stem Cell Transplantation 11Cytarabine 11Whole-Body Irradiation 10Biopsy 1010-propargyl-10-deazaaminopterin 10pembrolizumab 9fludarabine phosphate 9Specimen Handling 9Busulfan 9Mycophenolic Acid 8Granulocyte Colony-Stimulating Factor 8Depsipeptides 8Carmustine 8Bortezomib 8duvelisib 7Vorinostat 7Methotrexate 7Magnetic Resonance Spectroscopy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × entinostat × Clear all
NCT03925428 2020-09-28

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

National Cancer Institute (NCI)

Phase 1 Withdrawn
GastrointestinalLymphoid

Lymphoma, Pancreatic Neoplasms, Lymphoma, B-Cell, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡